TrialBreast cancer research : BCR2025

Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial.

Mei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.